Applications of a 7-day Caco-2 cell model in drug discovery and development

European Journal of Pharmaceutical Sciences

Volumn 56, Issue 1, 2014, Pages 120-130

  Peng, Ying ^a   Yadava, Preeti ^a   Heikkinen, Aki T ^b,c   Parrott, Neil ^b   Railkar, Aruna ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

7 day Caco 2 assay; Absorption modeling and prediction; ADME; Caco 2 permeability; Lead optimization (LO); Prodrug

Indexed keywords

ATENOLOL; ATORVASTATIN; CARBAMAZEPINE; CIMETIDINE; DESIPRAMINE; DOMPERIDONE; ELACRIDAR; ENALAPRILAT; FEXOFENADINE; FLUINDOSTATIN; FUROSEMIDE; GANCICLOVIR; GLYCYLPROLINE; HYDROCHLOROTHIAZIDE; INDINAVIR; KETOPROFEN; LISINOPRIL; METOPROLOL; NAPROXEN; PHENAZONE; PIROXICAM; PROPRANOLOL; QUINIDINE; RANITIDINE; SAQUINAVIR; SILDENAFIL; TERBUTALINE; UNINDEXED DRUG; VALGANCICLOVIR; VERAPAMIL; DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG PENETRATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; PH; PRIORITY JOURNAL; RAT; BIOASSAY; CACO 2 CELL LINE; INTESTINE ABSORPTION; METABOLISM;

BIOLOGICAL ASSAY; CACO-2 CELLS; DRUG DISCOVERY; HUMANS; INTESTINAL ABSORPTION; PHARMACEUTICAL PREPARATIONS;

EID: 84896935014     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.02.008     Document Type: Article

References (40)

1. Alsenz, J., Haenel, E., 2003. Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharm. Res. 20, 1961-1969. (Pubitemid 38005527)
2. Artursson, P., Karlsson, J., 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. commun. 175, 880-885.
3. Artursson, P., Palm, K., Luthman, K., 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46, 27-43.
4. Augustijns, P., Annaert, P., Heylen, P., Van den Mooter, G., Kinget, R., 1998. Drug absorption studies of prodrug esters using the Caco-2 model: evaluation of ester hydrolysis and transepithelial transport. Int. J. Pharm. 166, 45-53. (Pubitemid 28239738)
5. Bailey, C.A., Bryla, P., Malick, A.W., 1996. The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development. Adv. Drug Deliv. Rev. 22, 85-103. (Pubitemid 26423599)
6. Barr, W.H., Zola, E.M., Candler, E.L., Hwang, S.M., Tendolkar, A.V., Shamburek, R., Parker, B., Hilty, M.D., 1994. Differential absorption of amoxicillin from the human small and large intestine. Clinic. Pharmacol. Ther. 56, 279-285. (Pubitemid 24323919)
7. Behrens, I., Kissel, T., 2003. Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers? Eur. J. Pharm. Sci. 19, 433-442. (Pubitemid 36952405)
8. Chaturvedi, P.R., Decker, C.J., Odinecs, A., 2001. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr. Opin. Chem. Biol. 5, 452-463. (Pubitemid 32900519)
9. Chong, S., Dando, S.A., Soucek, K.M., Morrison, R.A., 1996. In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm. Res. 13, 120-123. (Pubitemid 26076307)
10. FDA, 2000. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA. Available at: 〈http://www.fda. gov/downloads/Drugs/.../Guidances/ucm070246.pdf〉.
11. Gertz, M., Houston, J.B., Galetin, A., 2011. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metabolism Dispos.: Biologic Fate Chem. 39, 1633-1642.
12. Guo, A., Biondi, D., Peng, Y., Pai, A., Renzetti, L., Railkar, A., 2003. Prioritizing compounds in early discovery for targeting the central nervous system (CNS). In: AAPS Annual Meeting. Avaliable at: 〈http://abstracts. aaps.org/SecureView/AAPSJournal/vtw8bu9ogmga722zg571.pdf〉.
13. Hayeshi, R., Hilgendorf, C., Artursson, P., Augustijns, P., Brodin, B., Dehertogh, P., Fisher, K., Fossati, L., Hovenkamp, E., Korjamo, T., Masungi, C., Maubon, N., Mols, R., Müllertz, A., Mönkkönen, J., O'Driscoll, C., Oppers-Tiemissen, H.M., Ragnarsson, E.G., Rooseboom, M., Ungell, A.L., 2008. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur. J. Pharm. Sci. 35, 383-396.
14. Heikkinen, A.T., Mönkkönen, J., Korjamo, T., 2009. Kinetics of cellular retention during Caco-2 permeation experiments: role of lysosomal sequestration and impact on permeability estimates. J. Pharmacol. Exp. Ther. 328, 882-892.
15. Heikkinen, A.T., Baneyx, G., Caruso, A., Parrott, N., 2012. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using gastroplus. Eur. J. Pharm. Sci. 47, 375-386.
16. Heikkinen, A.T., Fowler, S., Gray, L., Li, J., Peng, Y., Yadava, P., Railkar, A., Parrott, N., 2013. In vitro to in vivo extrapolation and physiologically based modeling of cytochrome p450 mediated metabolism in beagle dog gut wall and liver. Mol. Pharm. 10, 1388-1399.
17. Hidalgo, I.J., Raub, T.J., Borchardt, R.T., 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96, 736-749. (Pubitemid 19057595)
18. Hidalgo, I.J., 1996. Cultured intestinal epithelial cell models. Pharm. Biotechnol. 8, 35-50.
19. Hovgaard, L., Brondsted, H., 1995. Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancer effects of cyclodextrins. Pharm. Res. 12, 1328-1332.
20. Hyafil, F., Vergely, C., Du Vignaud, P., Grand-Perret, T., 1993. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53, 4595-4602. (Pubitemid 23304385)
21. Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E., Grove, J.R., 1999. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88, 28-33. (Pubitemid 29037364)
22. Jones, H.M., Parrott, N., Ohlenbusch, G., Lave, T., 2006. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin. pharmacokinet. 45, 1213-1226. (Pubitemid 44904824)
23. Kansy, M., Senner, F., Gubernator, K., 1998. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41, 1007-1010. (Pubitemid 28207375)
24. Lennernäs, H., 2007. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Current Drug Metabolism 8, 645-657. (Pubitemid 47578114)
25. Liang, E., Chessic, K., Yazdanian, M., 2000. Evaluation of an accelerated Caco-2 cell permeability model. J. Pharm. Sci. 89, 336-345. (Pubitemid 30152434)
26. Markowskaa, M., Oberlea, R., Juzwina, S., Hsua, C.-P., Gryszkiewiczb, M., Streeter, A.J., 2001. Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. J. Pharmacol. Toxicol. Methods 46, 51-55. (Pubitemid 34260896)
27. Murakami, T., Takano, M., 2008. Intestinal efflux transporters and drug absorption. Expert Opin. Drug Metabolism Toxicol. 4, 923-939.
28. Neuhoff, S., Ungell, A.L., Zamora, I., Artursson, P., 2003. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm. Res. 20, 1141-1148. (Pubitemid 36951837)
29. Nishimuta, H., Sato, K., Yabuki, M., Komuro, S., 2011. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metabolism Pharmacokinet. 26, 592-601.
30. Palmgren, J.J., Monkkonen, J., Korjamo, T., Hassinen, A., Auriola, S., 2006. Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur. J. Pharm. Biopharm. 64, 369-378. (Pubitemid 44585210)
31. Parrott, N., Lave, T., 2002. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur. J. Pharm. Sci. 17, 51-61. (Pubitemid 35287171)
32. Parrott, N., Lave, T., 2008. Applications of physiologically based absorption models in drug discovery and development. Mol. Pharm. 5, 760-775.
33. Sambuy, Y., De Angelis, I., Ranaldi, G., Scarino, M.L., Stammati, A., Zucco, F., 2005. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 21, 1-26. (Pubitemid 40767684)
34. Stewart, B.H., Chan, O.H., Lu, R.H., Reyner, E.L., Schmid, H.L., Hamilton, H.W., Steinbaugh, B.A., Taylor, M.D., 1995. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharmaceut. Res. 12, 693-699.
35. Stewart, B.H., Wang, Y., Surendran, N., 2000. Ex vivo approaches to predicting oral pharmacokinetics in humans. Annu. Rep. Med. Chem. 35, 299-307.
36. Sun, D., Lennernas, H., Welage, L.S., Barnett, J.L., Landowski, C.P., Foster, D., Fleisher, D., Lee, K.D., Amidon, G.L., 2002. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19, 1400-1416. (Pubitemid 35266543)
37. Thomsen, A.E., Christensen, M.S., Bagger, M.A., Steffansen, B., 2004. Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells. Eur. J. Pharm. Sci. 23, 319-325. (Pubitemid 39573382)
38. Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H., 2000. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Euro. J. Pharm. Sci. 10, 195-204. (Pubitemid 30190095)
39. Yamashita, S., Konishi, K., Yamazaki, Y., Taki, Y., Sakane, T., Sezaki, H., Furuyama, Y., 2002. New and better protocols for a short-term Caco-2 cell culture system. J. Pharm. Sci. 91, 669-679. (Pubitemid 34639630)
40. Yang, J., Jamei, M., Yeo, K.R., Tucker, G.T., Rostami-Hodjegan, A., 2007. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metabolism 8, 676-684. (Pubitemid 47578116)